Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors
NCT06177171Phase 1Active, not recruiting
- Start
- Feb 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib and inqovi in solid tumor (3 arms). Primary endpoints: Proportion of participants with treatment-emergent Adverse Events up to 2 years, Percentages of dose-limiting toxicities and 2 more. Started Feb 2024; status: active, not recruiting.
02
Drugs
olaparibinqovi
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06177171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06177171.